

PHARMACY COVERAGE GUIDELINE

THIOLA® (tiopronin) immediate release oral
THIOLA® EC (tiopronin delayed release) oral
Tiopronin immediate release oral
Tiopronin DR delayed release oral
Venxxiva (tiopronin delayed release) oral
Generic Equivalent (if available)

This Pharmacy Coverage Guideline (PCG):

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

Scope

- This PCG applies to Commercial and/or Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

Instructions & Guidance

- To determine whether a member is eligible for the Service, read the entire PCG.
- This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
- Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
- The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
- The “Description” section describes the Service.
- The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
- The “Resources” section lists the information and materials we considered in developing this PCG
- **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
- Information about medications that require prior authorization is available at www.azblue.com/pharmacy. You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to Pharmacyprecert@azblue.com.

Medical Necessity Requirements for THIOLA (tiopronin immediate release oral), THIOLA EC (tiopronin delayed release oral), Tiopronin (immediate release oral) generic, Tiopronin DR (delayed release oral) generic, Venxxiva (tiopronin delayed release oral) generic

Criteria for Initial Therapy:

Prescriber Qualifications

ORIGINAL EFFECTIVE DATE: 01/18/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 08/21/2025 | LAST CRITERIA REVISION DATE: 08/21/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

THIOLA® (tiopronin) immediate release oral
THIOLA® EC (tiopronin delayed release) oral
Tiopronin immediate release oral
Tiopronin DR delayed release oral
Venxxiva (tiopronin delayed release) oral
Generic Equivalent (if available)

- Prescribed by a Nephrologist or Urologist or in consultation with a Nephrologist or Urologist

Indication

- Severe Homozygous Cystinuria with Cystine Kidney Stone Formation

Age Requirement

- 9 years of age or older and weighs at least 20 kilograms

Baseline Clinical Evaluation

- Diagnosis confirmed by **ONE** or more of the following:
 - Stone analysis reveals 100 percent cystine calculi
 - Pathognomonic hexagonal cystine crystals visualized on urine microscopy
 - Genetic testing confirms two defects in any combination of the SLC7A9 and SLC3A1 genes
[Note: Genetic testing is not required for diagnosis cystinuria]
- Assessment for proteinuria before starting treatment with continued monitoring as clinically appropriate
- 24 hour urine collection shows urinary cystine greater than 400 milligrams per day
- Routine urinalysis
- Urinary cystine

Alternative Therapies

- Resistant to treatment with **ALL** the following conservative measures:
 - High fluid intake of at least 2 liters per day
 - Urinary alkalinization with potassium citrate (or other urinary alkalinizing agent) to maintain urine pH above 7
 - Diet modification with restricted sodium and protein intake

Brand Specific Criteria

- **Brand Thiola:** Have failure, contraindication or intolerance with **THREE** equivalents of **generic tiopronin immediate release** (when available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)
- **Brand Thiola EC and generic Venxxiva:** Have failure, contraindication or intolerance with **THREE** equivalents of **generic tiopronin delayed release** (when available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

Documentation Requirements

- A completed request form must be submitted, including:
 - Chart notes

ORIGINAL EFFECTIVE DATE: 01/18/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 08/21/2025 | LAST CRITERIA REVISION DATE: 08/21/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

THIOLA® (tiopronin) immediate release oral
THIOLA® EC (tiopronin delayed release) oral
Tiopronin immediate release oral
Tiopronin DR delayed release oral
Venxxiva (tiopronin delayed release) oral
Generic Equivalent (if available)

-
- Lab results (24 hour urinary cystine greater than 400 milligrams per day, urinalysis, urinary cystine)
 - Supporting clinical documentation

Initial Therapy Criteria Approval Duration:

- 12 months OR end of plan year

Criteria for Continuation of Therapy (renewal therapy):

Note: Manufacturer assistance (e.g., coupons, samples, etc.) are not considered for continuation of therapy

Prescriber Qualifications

- Continues to be seen by a physician specializing in or is in consultation with a Nephrologist or Urologist

Clinical Response

- Positive clinical response defined as **ALL** of the following:
 - Urinary cystine concentration is less than 250 milligrams per liter
 - Urine pH is greater than 7
 - Reduction in cystine stone production

Adherence

- Adherence to the prescribed therapy regimen has been documented

Brand Specific Criteria

- **Brand Thiola:** Have failure, contraindication or intolerance with **THREE** equivalents of **generic tiopronin immediate release** (when available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)
- **Brand Thiola EC and generic Venxxiva:** Have failure, contraindication or intolerance with **THREE** equivalents of **generic tiopronin delayed release** (when available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

Safety

- No significant adverse drug effects that may exclude continued use, including:
 - Hypersensitivity reaction
 - Renal complications of proteinuria or nephrotic syndrome
 - Membranous nephropathy

Documentation Requirements

ORIGINAL EFFECTIVE DATE: 01/18/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 08/21/2025 | LAST CRITERIA REVISION DATE: 08/21/20205

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

THIOLA® (tiopronin) immediate release oral
THIOLA® EC (tiopronin delayed release) oral
Tiopronin immediate release oral
Tiopronin DR delayed release oral
Venxxiva (tiopronin delayed release) oral
Generic Equivalent (if available)

-
- Chart notes
 - Supporting clinical documentation with evidence of improvement in cystinuria
 - Lab values confirming safe use (urinary cystine less than 250 milligrams per liter, urine pH greater than 7)

Continuation Therapy Criteria Approval Duration:

- 12 months OR end of plan year

Criteria for Off-Label Use Requests:

Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. Off-Label Use of Non-Cancer Medications
2. Off-Label Use of Cancer Medications

Description:

Tiopronin is indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine.

Efficacy of tiopronin for cystinuria comes from data from an uncontrolled trial in 66 patients with cystinuria age 9 to 68 years of age and clinical experience.

Tiopronin is a reducing and complexing thiol-glycine compound, it undergoes thiol-disulfide exchange with cysteine to form a mixed disulfide of tiopronin-cysteine. From this reaction, a water-soluble mixed disulfide is formed and the amount of sparingly soluble cystine is reduced.

Cystine is a homodimer of the amino acid cysteine. Patients with cystinuria have impaired renal cystine transport, with decreased proximal tubular reabsorption of filtered cystine resulting in increased urinary cystine excretion and cystine stones. Cystine stones occur in approximately 10,000 persons in the US who are homozygous for cystinuria. These persons excrete abnormal amounts of cystine in urine of > 250 mg/g creatinine. Almost all cases of cystinuria are accounted for by mutations in two genes specifically, *SLC3A1* and *SLC7A9*. People who are heterozygotes for mutations in both *SLC3A1* and *SLC7A9* do not usually form cystine stones.

Cystinuria is diagnosed among patients with nephrolithiasis and one or more of the following findings: positive family history of cystinuria; stone analysis showing cysteine; and identification of pathognomonic hexagcystine crystals on urinalysis (seen on initial urinalysis in approximately 25% of patients).

PHARMACY COVERAGE GUIDELINE

THIOLA® (tiopronin) immediate release oral
THIOLA® EC (tiopronin delayed release) oral
Tiopronin immediate release oral
Tiopronin DR delayed release oral
Venxxiva (tiopronin delayed release) oral
Generic Equivalent (if available)

Stone formation is determined primarily by the urinary supersaturation of cystine. Stone formation is the result of poor aqueous solubility of cystine. Cystine stones form when urinary cystine concentration exceeds the solubility limit. Cystine solubility in urine is pH-dependent, and ranges from 170-300 mg/liter at pH 5, 190-400 mg/liter at pH 7 and 220-500 mg/liter at pH 7.5. There are no known inhibitors of the crystallization of cystine.

The goal of therapy is to reduce urinary cystine concentration below its solubility limit. This is accomplished by dietary measure aimed at reducing cystine synthesis and by a high fluid intake in order to increase urine volume and thereby lower cystine concentration. It is possible to reduce the likelihood of cystine crystallization by: increasing fluid intake, which decreases the cystine concentration; restricting sodium and protein intake, which modestly reduces cystine excretion and, therefore, cystine concentration; and urinary alkalinization, which increases the solubility of cysteine. Alkalinizers include use of potassium citrate or potassium bicarbonate to obtain a target urine pH of 7 or greater. If conservative measures are unable to adequately reduce the urinary cystine concentration, or stones recur, adding a thiol-containing drugs such as penicillamine or tiopronin is usually tried. In some homozygous patients with severe cystinuria, urinary cystine exceeds 500 mg/day, penicillamine may be used. Like tiopronin, penicillamine undergoes thiol-disulfide exchange with cystine, thereby lowering the amount of sparingly soluble cystine in urine.

Definitions:

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting
[MedWatch Forms for FDA Safety Reporting | FDA](#)

Resources:

Thiola (tiopronin) tablet product information, revised by Mission Pharmacal Company 01-2024. Available at DailyMed
<http://dailymed.nlm.nih.gov>. Accessed May 13, 2025.

Tiopronin tablet product information, revised by Teva Pharmaceuticals USA, Inc. 04-2025. Available at DailyMed
<http://dailymed.nlm.nih.gov>. Accessed May 13, 2025.

Thiola EC (tiopronin) delayed release tablet product information, revised by Mission Pharmacal company 03-2021. Available at DailyMed
<http://dailymed.nlm.nih.gov>. Accessed May 13, 2025.

Tiopronin delayed release tablet product information, revised by Amneal Pharmaceuticals LLC. 05-2023. Available at DailyMed
<http://dailymed.nlm.nih.gov>. Accessed May 13, 2025.

Venxxiva (tiopronin) delayed release tablet product information, revised by Cycle Pharmaceuticals Ltd. 12-2024. Available at DailyMed
<http://dailymed.nlm.nih.gov>. Accessed May 13, 2025.

Goldfarb DS, Ferraro PM, Sas DJ, Baum MA. Cystinuria and cystine stones. In: UpToDate, Preminger GM, Lam AQ (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Literature current through May 2025. Topic last updated June 18, 2025. Accessed June 23, 2025.